Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
Medical journal publication during global stress / Professor Philip D Walson, MD
Is the local tolerance of injectable biosimilars too underestimated? / Professor Alain Astier, PharmD, PhD
A white paper: US biosimilars market on pace with Europe / Madelaine A Feldman, MD, FACR, Michael S Reilly, Esq
Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags / Jolita Seckute, PhD, Ingrid Castellanos, PhD, Steven Bane, PhD
Local policies on biosimilars: are they designed to optimize use of freed resources? / Arianna Bertolani, PhD; Claudio Jommi, MS
Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector / K Canham, C Newcomb
Biosimilars – status in July 2020 in 16 countries / Hye-Na Kang, Robin Thorpe, Ivana Knezevic, Daehyun Baek, Parichard Chirachanaku, Hui Ming Chua, Dina Dalili, Freddie Foo, Kai Gao, Suna Habahbeh, Hugo Hamel, Edwin Nkansah, Maria Savkina, Oleh Semeniuk, Shraddha Srivastava, João Tavares Neto, Meenu Wadhwa, Teruhide Yamaguchi
Prices of cancer medicines across Europe; findings and implications for the future / Brian Godman, BSc, PhD; Steven Simoens, MSc, PhD; Amanj Kurdi, BSc, PhD; Gisbert Selke; John Yfantopoulos; Andrew Hill, PhD, et al.
An assessment of trends in the Iranian pharmaceutical market following domestic production of selected medications (2007‒2017) and new considerations for health policymakers / Marzieh Zargaran, PhD Candidate; Abdol Majid Cheraghali, PharmD, PhD; Fatemeh Soleymani, PharmD, PhD; Rajabali Daroudi, BSc, MSc, PhD; Ali Akbari Sari, MD, PhD; Shekoufeh Nikfar1, PharmD, MPH, PhD
Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching / Mansour Somaily, MD; Hana Alahmari, MD; Wejdan Abbag; Shahenda Yousif, MD; Nawar Tayfour, MD; Nouf Almushayt; Saleh Alhusayni, MD; Saeed Almajadiah, MD
Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study / Pieter J Glerum, MSc; Mert Hayta, PharmD, MSc; David M Burger, PharmD, PhD; Cees Neef, PharmD, PhD; Marcel L Bouvy, PharmD, PhD; Marc Maliepaard, PhD
Pharmaceutical Data Integrity: issues, challenges and proposed solutions for manufacturers and inspectors / Chan Lai Wah, BSc (Pharm) (Hons), PhD; Professor Sia Chong Hock, BPharm, MSc; Vernon Tay, BSc (Pharm) (Hons); Vimal Sachdeva, MSc
An overview of the current status and future perspectives of the biosimilars and follow-on biologics in Iran / Farhang Rezaei, PharmD; Nassim Anjidani
Continuous manufacturing versus batch manufacturing: benefits, opportunities and challenges for manufacturers and regulators / Adjunct Associate Professor Sia Chong Hock, BSc (Pharm), MSc; Teh Kee Siang, Associate Professor Chan Lai Wah, BSc (Pharm) (Hons), PhD
The EU biosimilar framework – experience to date. The EU regulatory network and emerging trends – a review of quality, safety and clinical development programmes / Marta Zuccarelli, PharmD; Benjamin Micallef, PharmD; Mark Cilia, PharmD; Anthony Serracino-Inglott, PharmD; Professor John-Joseph Borg, PhD
Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD
Local policies on biosimilars – are they designed to optimize use of freed resources; findings and implications? / Brian Godman, BSc, PhD; Eleonora Allocati, BSc, MSc; Evelien Moorkens, BSc, MSc; Hye-Young Kwon, BPharm, MPH, PhD
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.